peptide
Semaglutide
strongFDA-Approved· RxInjectionOral
Active ingredient in Ozempic/Wegovy. Mimics GLP-1 to signal fullness and slow gastric emptying. STEP trials showed 14.9% weight loss at 68 weeks.
Key facts
- Classification
- Semaglutide is a GLP-1 receptor agonist with Aib at position 8 for DPP-4 resistance and a C-18 fatty diacid chain enabling albumin binding (~7-day half-life).
- Primary benefits
- Fat Loss (10/10) · Longevity (5/10) · Gut Health (4/10)
- Administration
- Injection, Oral
- Doses studied
- Start at 0.25 mg per week subq and gradually increase to 1-2.4 mg per week over several months. An FDA-approved oral formulation (Rybelsus) is also available at 3-14 mg daily. Meant for long-term use.
- Evidence strength
- Strong — 21 peer-reviewed studies
- Stacks well with
- 5-Amino-1MQ, BPC-157, MOTS-c
- Legal status
- FDA-Approved · prescription required · WADA prohibited
Quick stats
- Type
- Peptide
- Administration
- Injection, Oral
- Studies referenced
- 21
- Stacks with
- 3 peptides
- Regulatory
- FDA-Approved
Scientific overview
Semaglutide is a GLP-1 receptor agonist with Aib at position 8 for DPP-4 resistance and a C-18 fatty diacid chain enabling albumin binding (~7-day half-life). Enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite via hypothalamic GLP-1 receptors. STEP 1 showed 14.9% weight reduction at 68 weeks.
Goal coverage · Semaglutide
🔥 Fat Loss10/10
⏳ Longevity5/10
🫃 Gut Health4/10
🧊 Inflammation3/10
Medical oversight requiredNot safe during pregnancy· 6 contraindications